Abstract
Background: Health-related quality of life (HRQOL) is a major clinical outcome for heart failure (HF) patients. We aimed to determine the frequency, durability, and prognostic significance of improved HRQOL after hospitalization for decompensated HF. Methods and Results: We analyzed HRQOL, measured serially using the Minnesota Living with Heart Failure Questionnaire (MLHFQ), for 425 patients who survived to discharge in a multicenter randomized clinical trial of pulmonary artery catheter versus clinical assessment to guide therapy for patients with advanced HF. All patients enrolled had 1 or more prior HF hospitalizations or chronic high diuretic doses and 1 or more symptom and 1 sign of fluid overload at admission. Improvement, defined as a decrease of more than 5 points in MLHFQ total score, occurred in 68% of patients by 1 month and stabilized. The degree of 1-month improvement differed (P < .0001 group × time interaction) between 6-month survivors and non-survivors. In a Cox regression model, after adjustment for traditional risk factors for HF morbidity and mortality, improvement in HRQOL by 1 month compared to worsening at 1 month or no change predicted time to subsequent event-free survival (P = .013). Conclusions: In patients hospitalized with severe HF decompensation, HRQOL is seriously impaired but improves substantially within 1 month for most patients and remains improved for 6 months. Patients for whom HRQOL does not improve by 1 month after hospital admission merit specific attention both to improve HRQOL and to address high risk for poor event-free survival.
Original language | English |
---|---|
Pages (from-to) | 763-769 |
Number of pages | 7 |
Journal | Journal of Cardiac Failure |
Volume | 15 |
Issue number | 9 |
DOIs | |
State | Published - Nov 2009 |
Bibliographical note
Funding Information:The Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial 12 offered a unique opportunity to examine questions about HRQOL in patients with advanced or end-stage HF. The ESCAPE trial was sponsored by a grant from the National Heart Lung and Blood Institute and conducted at 26 academic HF and transplantation centers in the United States and Canada.
Keywords
- Heart failure
- quality of life
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine